SRT1720 HCl

For research use only.

Catalog No.S1129

120 publications

SRT1720 HCl Chemical Structure

CAS No. 1001645-58-4

SRT1720 HCl is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3. SRT1720 induces autophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 238 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
USD 2470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's SRT1720 HCl has been cited by 120 publications

Purity & Quality Control

Choose Selective Sirtuin Inhibitors

Biological Activity

Description SRT1720 HCl is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3. SRT1720 induces autophagy.
Targets
SIRT1 [1]
(Cell-free assay)
0.16 μM(EC50)
In vitro

The maximum activation ratio of SRT1720 versus the closest sirtuin homologues, SIRT2 (EC1.5 = 37 μM) and SIRT3 (EC1.5 > 300 μM) is up to 781%. SRT1720 binds to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. SRT1720 could reduce fed glucose levels. Glucose excursion during an intraperitoneal glucose tolerance test is also significantly reduced in the SRT1720 group, and comparable to rosiglitazone, a PPARγ activator that has been used to treat type 2 diabetes. SRT1720 does not have an effect on fasting glucose in chow-fed mice, revealing that pharmacological SIRT1 activation is unlikely to induce hypoglycaemia. SRT1720 significantly reduces the hyperinsulinaemia after 4 weeks, partially normalizing increased insulin levels similar to rosiglitazone treatment. SRT1720 treatment increases mitochondrial capacity by 15% in gastrocnemius muscle as measured by citrate synthase activity. [1] Higher concentrations of SRT1720 (15 μM) induces a modest (10-20%) decrease in normal cell viability. SRT1720 also significantly inhibits VEGF-dependent MM cell migration. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CACs  NYj1RVZITnWwY4Tpc44hSXO|YYm= M1vhb|TDqM7:TR?= MXSzNOKhdWmw NF7PSWRFVVOR NFnObm9qdmS3Y3XzJIFkfXSnIGPJVnQyKGGldHn2ZZRqd28EoB?= NV7DWZNPOjZ{NUSxNFQ>
MC3T3-E1 MX;GeY5kfGmxbjDBd5NigQ>? NWWzSIJROTBiwsXNxsA> MY[xJIg> NYTJbINHemWmdXPld{B1cGViVFfGMe6zNXO2aX31cIF1\WRiVlXHSkBz\WynYYPlJIlvKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYNCpC=> NUi5UIlQOjZzM{[5O|g>
MC3T3-E1 NWnGO|VGTnWwY4Tpc44hSXO|YYm= NFXDOWQyOCEEtV5CpC=> NYPB[3dVOTJiaB?= NGrnbmFz\WS3Y3XzJJRp\SCYRVfGJI1TVkFiZYjwdoV{e2mxbjDs[ZZmdHNic4TpcZVt[XSnZDDifUBVT0ZvzsK= MlfONlYyOzZ7N{i=
MC3T3-E1 Ml7USpVv[3Srb36gRZN{[Xl? MkPpNlAh|ryP M2PES|EhcA>? MWPzeZBxemW|c3XzJJRp\SCWR1[t{tIucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gc4YheDR2L4C0NkBOSVBia3nuZZNmKG:{IGPBVGswUk6N MljDNlYyOzZ7N{i=
WE-68 NHHHd5BCeG:ydH;zbZMhSXO|YYm= MUGwMVI1KM7:TR?= NH7nfIczPCCq M1npNIlv\HWlZYOgZ4VtdCCmZXH0bEBqdiCmb4PlJIRmeGWwZHXueIx6 Ml3YNlYxPTV6MEW=
SK-ES-1 M2L4dWFxd3C2b4Ppd{BCe3OjeR?= MmXZNE0yOCEQvF2= MkDJNlQhcA>? NVmzcJhCcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHTvd4Uh\GWyZX7k[Y51dHl? MU[yOlA2PThyNR?=
SK-N-MC  MlzSRZBweHSxc3nzJGF{e2G7 MljZNE0zNjVizszN NH;ZdHYzPCCq M2rqc4lv\HWlZYOgZ4VtdCCmZXH0bEBqdiCmb4PlJIRmeGWwZHXueIx6 NWjqfIFROjZyNUW4NFU>
WE-68 MnTrSpVv[3Srb36gRZN{[Xl? MUKyNEDPxE1? NUTvc4FxOC1{NDDo MnvkZYN1cX[jdHXzJINie3Cjc3WgN{84 M33xUFI3ODV3OEC1
SK-ES-1 NGfQVI1HfW6ldHnvckBCe3OjeR?= NVvnbox6OTBizszN M2fvXlAuOjRiaB?= NET5cppi[3SrdnH0[ZMh[2G|cHHz[UA{Nzd? NUK1S|Q1OjZyNUW4NFU>
SK-N-MC  NHK1ZplHfW6ldHnvckBCe3OjeR?= MXqzJO69VQ>? NGP0b|gxNTJ2IHi= M1rPRoFkfGm4YYTld{Bk[XOyYYPlJFMwPw>? Moq5NlYxPTV6MEW=
NRK-49F M2jYd2Z2dmO2aX;uJGF{e2G7 M3PYSFDjiJN{wrFOwG0> Mn\DN|YhcA>? MnfSbY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZizsGtV21CKGGwZDDmbYJzd26nY4TpckBld3OnIHTldIVv\GWwdHz5 M{H4dFI3ODJ{MECz
NRK-49F M{DuZmZ2dmO2aX;uJGF{e2G7 NHjNXFkx6oDVMtMg{txO M4rQPFM3KGh? NVzxR2pC\W6qYX7j[ZMheGixc4Doc5J6dGG2aX;uJI9nKEWJRmKgZY5lKFCGR1\S{tLDqA>? MXGyOlAzOjByMx?=
NRK-49F NFTGWIhHfW6ldHnvckBCe3OjeR?= Mk\oNQKBmzMEoN88US=> NFXGfWw{PiCq M2LYUIVvcGGwY3XzJHNVSVR|IIDoc5NxcG:{eXzheIlwdg>? M4LKV|I3ODJ{MECz
RAW264.7 NFi0TFJHfW6ldHnvckBCe3OjeR?= M1zOOFEh|ryP MVG2JIg> MWH1dJJm\3WuYYTld{B1cGVicnXkeYNm\CCVSWLUNUBxem:2ZXnuJI9zKG2UTlGgcIV3\Wy|IHL5JIhq\2hiZ3z1Z49{\Q>? NGjIZW4zPTd7M{m5OS=>
MCF10A Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjyNE0zOCEQvF2= NEHJUVUzPCCq NF:5T2xz\WS3Y3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MYiyOVQyOTN3Nh?=
MCF-7 M4\NXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\WeoExNTJyIN88US=> NH3tfYgzPCCq MYDy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> MoLHNlU1OTF|NU[=
T47D MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\1NE0zOCEQvF2= NVHPSVBjOjRiaB?= MnzYdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MlLLNlU1OTF|NU[=
SKBR3 M2PwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFS2d20xNTJyIN88US=> Mnn5NlQhcA>? MXLy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> MV6yOVQyOTN3Nh?=
MDA-MB-231 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUewMVIxKM7:TR?= NF7qRogzPCCq NV3Dc5c3emWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MlHwNlU1OTF|NU[=
SUM149 M1TxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorVNE0zOCEQvF2= NYPWdGpmOjRiaB?= NVXXU5M2emWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M4W2XFI2PDFzM{W2
HS578T NXnVNVZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnUWmZMOC1{MDFOwG0> M1XhNlI1KGh? NUmybmVXemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MYOyOVQyOTN3Nh?=
BT20 NWrC[Zl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG0NE0zOCEQvF2= MXKyOEBp NXL0SFg6emWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M2PPRlI2PDFzM{W2
A459 M4i2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFH1VGcxNTJyIN88US=> MWiyOEBp MVXy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> NEfUXXAzPTRzMUO1Oi=>
HCT116 MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy2bpQxNTJyIN88US=> NYT2V|A5OjRiaB?= M3;r[pJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NXLQb4FrOjV2MUGzOVY>
Neu NVfJN3VPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTDd2kxNTJyIN88US=> MW[yOEBp M{fyfZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NFzSdlQzPTRzMUO1Oi=>
MDA-MB-231 NELKVJZHfW6ldHnvckBCe3OjeR?= MlfVOUDPxE1? NUfVU2pPQCCq MXfpcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCjY3nkbYMhfmW|aXP1cIFzKG:{Z3Hu[Yxt\XN? NWfYcWMxOjV2MUGzOVY>
MDA-MB-231 NIj2eVdHfW6ldHnvckBCe3OjeR?= M{jRS|Uh|ryP MWOxOkBp NUe2Spk3cW6mdXPld{BtgXOxc3;tZYwhdWWvYoLhcoUheGW{bXXhZoltcXqjdHnvci=> NH;rcmIzPTRzMUO1Oi=>
MC3T3-E1 M4fRO2Z2dmO2aX;uJGF{e2G7 MkfBNVAh|ryP MUi2NEBucW8EoB?= MnnTd5VxeHKnc4Pld{B1cGViRlfGMVIue3SrbYXsZZRm\CCxc4Tlc5Bzd3SnZ3XybY4hemWuZXHz[S=> MlzyNlUzQTByOUW=
MC3T3-E1 NFrEUZBHfW6ldHnvckBCe3OjeR?= M2DrblExKM7:TR?= MVi2NEBucW8EoB?= M3mxR4F1fGWwdXH0[ZMhfGinIF\HSk0zNWmwZIXj[YQhd3O2ZX;wdo91\WencnnuJI1TVkFiZYjwdoV{e2mxbh?= NGfvR3QzPTJ7MEC5OS=>
MC3T3-E1 Mk[2SpVv[3Srb36gRZN{[Xl? M2T1flExKM7:TR?= NFr3fGo3OCCvaX9CpC=> M2nycYF1fGWwdXH0[ZMhfGinIF\HSk0zNWmwZIXj[YQhd3O2ZX;wdo91\WencnnuJI1TVkFiZYjwdoV{e2mxbh?= MnLyNlUzQTByOUW=
MC3T3-E1 MVTGeY5kfGmxbjDBd5NigQ>? MUexNEDPxE1? MmHDOlAhdWmwwrC= M{nnVpN2eHC{ZYPz[ZMhfGinIFLNVE01NXO2aX31cIF1\WRiVlXHSkBz\WynYYPl NEnE[pUzPDR|NUS0OC=>
MC3T3-E1 NVLSeXZ{TnWwY4Tpc44hSXO|YYm= MmL5NVAh|ryP MUi2NEBucW8EoB?= NHK2TJN{fXCycnXzd4V{KHSqZTDQS2Yz|rFvc4TpcZVt[XSnZDDPVGchemWuZXHz[S=> MmjqNlQ{OzN|M{[=
MC3T3-E1 NUXpeWR3TnWwY4Tpc44hSXO|YYm= NV\aTIh[OTBizszN NVnCUXVKPjBibXnuxsA> M4K4d5Jm\HWlZYOgeIhmKFCJRkNOtU1{fGmvdXzheIVlKHCqb4PwbI9zgWyjdHnvckBw\iCyNESvdFQzKE2DUDDrbY5ie2V? M4fp[lI1OzN|M{O2
MC3T3-E1 M1vPR2Z2dmO2aX;uJGF{e2G7 NWfZNWVbOTBizszN NX\HPYhyPjBibXnuxsA> M1zoO4F1fGWwdXH0[ZMhfGinIGDHSlLPuS2rbnT1Z4VlKHCqb4PwbI9zgWyjdHnvckBw\iCkb4ToJG1GUzFxMjDhcoQhWmGoLUG= NIqxWowzPDN|M{OzOi=>
RPE MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MU[1JOK2VQ>? M2PKflEhcA>? M4rYeoF1fGWwdXH0[ZMhV0IQsj3pcoR2[2WmIHTlZ5Jm[XOnIH;mJINmdGxidnnhZoltcXS7 NGqxVIMzPDB|NkmzPC=>
9607 NULJcJpQS2WubDDWbYFjcWyrdImgRZN{[Xl? NUjrXGw6OSEQvF2= M3uzc|M3KGh? NVjMWpdNcW6lcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClb33wZZJm\CC5aYToJI1mdGG2b37pckBidG:wZR?= MnrMNlM4OjZ7NEm=
9607 M4r2cmZ2dmO2aX;uJGF{e2G7 NELzcmQyKM7:TR?= MkjCN|YhcA>? MXzpcoNz\WG|ZYOgV2lTXDFiYX7kJIRm[3KnYYPl[EBi[2W2eXzheIVlNXB3MzDlfJBz\XO|aX;u NXTzXoVVOjN5Mk[5OFk>
RPMI.8226 NYix[4dtS2WubDDWbYFjcWyrdImgRZN{[Xl? MXK3M|ExKM7:TR?= MVyyOEBp NF3SO4Vl\WO{ZXHz[ZMhfmmjYnnsbZR6KGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> MYKyNVk2ODd{OB?=
U266 M4G3SGNmdGxiVnnhZoltcXS7IFHzd4F6 M37rUVcwOTBizszN MUCyOEBp NFX0OI1l\WO{ZXHz[ZMhfmmjYnnsbZR6KGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> NF7IV3UzOTl3MEeyPC=>
MM.1S MoD3R4VtdCCYaXHibYxqfHliQYPzZZk> NYrPTZJtPy9zMDFOwG0> NEPXfYYzPCCq M2PYc4Rm[3KnYYPld{B3cWGkaXzpeJkh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> Mlj0NlE6PTB5Mki=
KMS12 MUDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Ml\rO{8yOCEQvF2= NGrReVAzPCCq MnOy[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 MoDBNlE6PTB5Mki=
LR5 Mlf4R4VtdCCYaXHibYxqfHliQYPzZZk> NEHyfIw4NzFyIN88US=> MkOzNlQhcA>? Ml:w[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 MVKyNVk2ODd{OB?=
MM.1R MonSR4VtdCCYaXHibYxqfHliQYPzZZk> MWi3M|ExKM7:TR?= MlPsNlQhcA>? MUTk[YNz\WG|ZYOgeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= NHrDfFAzOTl3MEeyPC=>
Ina6 NGHwdIhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUe3M|ExKM7:TR?= NU[xfGF6OjRiaB?= MkXo[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 M3\5SVIyQTVyN{K4
RPMI-8226 M37pbWFxd3C2b4Ppd{BCe3OjeR?= MXO3M|ExKM7:TR?= NFK2[GEzPCCq NETVNG9qdmS3Y3XzJIEhe2mpbnnmbYNidnRiaX7jdoVie2ViaX6geIhmKEGwbnX4bY4hXitxUFpijLLDqGGyb4D0c5Nqew>? MXeyNVk2ODd{OB?=
MM.1R  MnfhRZBweHSxc3nzJGF{e2G7 MlzKO{8yOCEQvF2= M4PSZlI1KGh? MmmzbY5lfWOnczDhJJNq\26rZnnjZY51KGmwY4LlZZNmKGmwIITo[UBCdm6neHnuJHYsN1CL4pkSxsBieG:ydH;zbZM> NEfZW3AzOTl3MEeyPC=>
H411EC3 NID0[4hHfW6ldHnvckBCe3OjeR?= NIrhSZY2OC9zMECgcm0> MVO2JIg> NXXYeItCcW6lcnXhd4V{KFOLUmSxJIFkfGm4aYT5JIlvKHSqZTDwdoV{\W6lZTDv[kBVW0FuIGDFVGNMKGGldHn2bZR6NCCvUl7BJIxmfmWuczDv[kBR[2tzIHHu[EBR\2NzzsGsJIFv\CCnbHX2ZZRqdmdiZ3z1Z49{\SCycn;keYN1cW:w NUDVS|ZbOjF{MUKwPVY>
hepatocytes NFWzTINHfW6ldHnvckBCe3OjeR?= MmTXNVAhdk1? NH;iR2Q3KGh? NUHSXJhxcW6lcnXhd4V{KFOLUmSxJIFkfGm4aYT5JIlvKHSqZTDwdoV{\W6lZTDv[kBVW0FuIGDFVGNMKGGldHn2bZR6NCCvUl7BJIxmfmWuczDv[kBR[2tzIHHu[EBR\2NzzsGsJIFv\CCnbHX2ZZRqdmdiZ3z1Z49{\SCycn;keYN1cW:w MYOyNVIyOjB7Nh?=
hepatocytes NYOwV445TnWwY4Tpc44hSXO|YYm= MoHCNVAhdk1? NVewOlRzPiCq NIjCRlZqdmO{ZXHz[ZMhUG2pY4NCpIFv\MLiQXPjxsBo\W6nIHX4dJJme3Orb36= MoniNlEzOTJyOU[=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Cleaved-PARP-1 / Cleaved-caspase-3 / LC3-II / p62 / SIRT1; 

PubMed: 26655844     


SU86.86 cells were transfected with control siRNA, SIRT1 siRNA#1, or DBC1 siRNA. 24 hours after transfection, cells were re-plated and allowed to attach for 24 hours. Cells were then treated with vehicle (control) or 5 μM SRT1720 for 16 hours. Expression 䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෕Ð鑸᎒彿堙奋堙巫堙

26655844
Immunofluorescence
Cathepsin B; 

PubMed: 26655844     


SU86.86 cells were incubated with vehicle or 5 μM SRT1720 for 5 hours for LysoTracker Red labeling and 16 hours for cathepsin B immunofluorescence, followed by DAPI staining.

26655844
Growth inhibition assay
Cell viability ; 

PubMed: 25411356     


MTT viability assay of cancer cell lines treated with different doses of SRT1720 for 24 hours. 

25411356
In vivo In DIO mice SRT1720 mimics several of the effects observed after calorie restriction including improved insulin sensitivity, normalized glucose and insulin levels, and increased mitochondrial capacity. In addition, in diet-induced obese and genetically obese mice, SRT1720 improves insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. Thus, SRT1720 is a promising new therapeutic agent for treating diseases of ageing such as type 2 diabetes. Consistent with improved glucose tolerance, the glucose infusion rate required to maintain euglycaemia is approximately 35% higher in SRT1720-treated fa/fa rats, and the total glucose disposal rate is increased by approximately 20%. [1] SRT1720 also prevents multiple myeloma tumor growth. SRT1720 increases the cytotoxic activity of bortezomib or dexamethasone. [2]

Protocol

Kinase Assay:[1]
- Collapse

SIRT1 fluorescence polarization assay:

In the SIRT1 FP assay, SIRT1 activity is monitored using a 20 amino acid peptide (Ac-Glu-Glu-Lys(biotin)-Gly-Gln-Ser-Thr-Ser-Ser-His-Ser-Lys(Ac)-Nle-Ser-Thr-Glu-Gly–Lys(MR121 or Tamra)-Glu-Glu-NH2) derived from the sequence of p53. The peptide is N-terminally linked to biotin and C-terminally modified with a fluorescent tag. The reaction for monitoring enzyme activity is a coupled enzyme assay where the first reaction is the deacetylation reaction catalyzed by SIRT1 and the second reaction is cleavage by trypsin at the newly exposed lysine residue. The reaction is stopped and streptavidin is added in order to accentuate the mass differences between substrate and product. The sensitivity of the FP assay allows identification of SRT1720. The fluorescence polarization reaction conditions are as follows: 0.5 μM peptide substrate, 150 μM βNAD+, 0-10 nM SIRT1, 25 mM Tris-acetate pH 8, 137 mM Na-Ac, 2.7 mM K-Ac, 1 mM Mg-Ac, 0.05% Tween-20, 0.1% Pluronic F127, 10 mM CaCl 2, 5 mM DTT, 0.025% BSA, and 0.15 mM nicotinamide. The reaction is incubated at 37 °C and stopped by addition of nicotinamide, and trypsin is added to cleave the deacetylated substrate. This reaction is incubated at 37 °C in the presence of 1 μM streptavidin. Fluorescent polarization is determined at excitation (650 nm) and emission (680 nm) wavelengths.
Cell Research:[2]
- Collapse
  • Cell lines: Human vascular endothelial cells (HUVECs)
  • Concentrations: 5 μM
  • Incubation Time: 2 hours
  • Method: Transwell Insert Assays are utilized to measure migration. In vitro angiogenesis is assessed by Matrigel capillary-like tube structure formation assay. For endothelial tube formation assay, human vascular endothelial cells (HUVECs) are obtained from Clonetics and maintained in endothelial cell growth medium-2 containing 5% FBS. After three passages, HUVEC cell viability is measured with the trypan blue exclusion assay, and <5% of cell death is observed with SRT1720 treatment.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Chase-SCID mice with MM.1S cells
  • Dosages: 200 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (75.09 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 506.02
Formula

C25H23N7OS.HCl

CAS No. 1001645-58-4
Storage powder
in solvent
Synonyms N/A
Smiles C1CN(CCN1)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=NC6=CC=CC=C6N=C5.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can we prepare Srt1720 for in vivo mouse studies?

  • Answer:

    SRT1720 HCl can be dissolved in 30% PEG 400+0.5% Tween 80+5% Propylene glycol at 30mg/ml as a suspension. It is fine for oral gavage. And we’ve also found that it can be dissolved in 2% DMSO+30% PEG 300+1%Tween 80+ddH2O at 3mg/ml clearly, which could be used for injection. When prepare the solution, please dissolve the compound in DMSO clearly first, then add PEG and Tween. After they mixed well, dilute with water.

Sirtuin Signaling Pathway Map

Related Sirtuin Products

Tags: buy SRT1720 HCl | SRT1720 HCl supplier | purchase SRT1720 HCl | SRT1720 HCl cost | SRT1720 HCl manufacturer | order SRT1720 HCl | SRT1720 HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID